Hunan Er-Kang Pharmaceutical Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Qingrong Sun

Chief Executive Officer (CEO)

CN¥335.7k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	5yrs
Participación del CEO	n/a
Permanencia media de la dirección	5yrs
Promedio de permanencia en la Junta Directiva	3.5yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Qingrong Sun (38 yo)

5yrs

Permanencia

CN¥335,700

Compensación

Mr. Qingrong Sun is General Manager of Hunan Er-Kang Pharmaceutical Co., Ltd from November 14, 2019 and serves as Director from November 14, 2022. He joined Hunan Er-Kang Pharmaceutical Co., Ltd. in July 2...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Qingrong Sun	GM & Non-Independent Director	5yrs	CN¥335.70k	sin datos
Zhao Xun	CFO & Non Independent Director	no data	CN¥389.10k	sin datos
Xiangyang Shi	Deputy GM & Non Independent Director	no data	CN¥535.10k	sin datos
Jishun Gu	Deputy GM & Board Secretary	4.7yrs	CN¥514.20k	0.0017% CN¥ 108.0k
Licheng Zhang	Deputy General Manager	no data	CN¥422.70k	sin datos
Wang Hui	Deputy General Manager	5yrs	CN¥365.30k	sin datos

5.0yrs

Permanencia media

42.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 300267 es experimentado (5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Qingrong Sun	GM & Non-Independent Director	2yrs	CN¥335.70k	sin datos
Zhao Xun	CFO & Non Independent Director	5yrs	CN¥389.10k	sin datos
Xiangyang Shi	Deputy GM & Non Independent Director	6.2yrs	CN¥535.10k	sin datos
Fangwen Shuai	Chairman of the Board	no data	CN¥512.60k	41.38% CN¥ 2.6b
Junwen Wang	Independent Director	5yrs	CN¥150.00k	sin datos
Wuzhen Jiang	Independent Director	5yrs	CN¥150.00k	sin datos
Qing Peng	Chairman of Supervisory Board	3.5yrs	sin datos	sin datos
Xue Tan	Independent Director	2yrs	CN¥150.00k	sin datos
Haiyi Li	Non-Employee Supervisor	2yrs	sin datos	sin datos
Hong Wang	Supervisor	2yrs	sin datos	sin datos

3.5yrs

Permanencia media

50yo

Promedio de edad

Junta con experiencia: La junta directiva de 300267 se considera experimentada (3.5 años de antigüedad promedio).

Hunan Er-Kang Pharmaceutical Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Hunan Er-Kang Pharmaceutical Co., Ltd, Annual General Meeting, May 17, 2024

Hunan Er-Kang Pharmaceutical Co., Ltd Announces Executive Changes

Insufficient new directors

High number of new and inexperienced directors

Recent updates

Third quarter 2024 earnings released: CN¥0.015 loss per share (vs CN¥0.006 loss in 3Q 2023)

New major risk - Share price stability

Hunan Er-Kang Pharmaceutical Co., Ltd to Report Q3, 2024 Results on Oct 25, 2024

Second quarter 2024 earnings released: EPS: CN¥0.002 (vs CN¥0.013 in 2Q 2023)

New minor risk - Share price stability

Hunan Er-Kang Pharmaceutical Co., Ltd to Report First Half, 2024 Results on Aug 29, 2024

Hunan Er-Kang Pharmaceutical Co., Ltd, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: CN¥0.095 loss per share (vs CN¥0.022 profit in FY 2022)

Hunan Er-Kang Pharmaceutical Co., Ltd to Report Q1, 2024 Results on Apr 27, 2024

Hunan Er-Kang Pharmaceutical Co., Ltd to Report Fiscal Year 2023 Results on Apr 25, 2024

Third quarter 2023 earnings released

Second quarter 2023 earnings released: EPS: CN¥0.013 (vs CN¥0.004 in 2Q 2022)

Hunan Er-Kang Pharmaceutical Co., Ltd Announces 2022 Final Profit Distribution, Payable on 09 June 2023

Hunan Er-Kang Pharmaceutical Co., Ltd Approves 2022 Profit Distribution Plan

First quarter 2023 earnings released: EPS: CN¥0.013 (vs CN¥0.011 in 1Q 2022)

Hunan Er-Kang Pharmaceutical Co., Ltd Announces Executive Changes

Insufficient new directors

Third quarter 2022 earnings released: EPS: CN¥0.003 (vs CN¥0.026 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.004 (vs CN¥0.024 in 2Q 2021)

Full year 2021 earnings released: CN¥0.38 loss per share (vs CN¥0.098 profit in FY 2020)

High number of new and inexperienced directors

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.026 (vs CN¥0.056 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.024 (vs CN¥0.021 in 2Q 2020)

Hunan Er-Kang Pharmaceutical Co., Ltd Announces 2020 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 09, June 2021

Hunan Er-Kang Pharmaceutical Co., Ltd Approves Final Cash Dividend for the Year 2020

First quarter 2021 earnings released: EPS CN¥0.026 (vs CN¥0.012 in 1Q 2020)

Hunan Er-Kang Pharmaceutical Co., Ltd Proposes Final Cash Dividend for the Year 2020

New 90-day low: CN¥3.79

New 90-day low: CN¥4.17

New 90-day low: CN¥4.62

Third quarter earnings released

Huang Shubiao, Xiao Qingguang, Wu Kaijian, and Huang Linggang completed the acquisition of 95% stake in Guangdong Yueerkang Pharmaceutical Co., Ltd. from Hunan Er-Kang Pharmaceutical Co., Ltd (SZSE:300267).

New 90-day high - CN¥5.23

First half earnings released

Hunan Er-Kang Pharmaceutical Co., Ltd to Report First Half, 2020 Results on Aug 28, 2020

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad